GI
GALT icon

GAMMA Investing’s Galectin Therapeutics GALT Stock Holding History

GAMMA Investing’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$644 Buy
+166
New +$641 ﹤0.01% 4179

Other funds holding GALT

AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's GALT Position: Q3 2026 in Review

GAMMA Investing opened a new position in Galectin Therapeutics (GALT) in Q3 2026: 166 shares worth $644. The stake represents ﹤0.01% of the portfolio and ranks #4179 among its holdings.

4 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

  • GAMMA Investing held 166 shares of Galectin Therapeutics worth $644 as of Q3 2026.
  • Galectin Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Galectin Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4179 holding.
  • 4 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.